COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency.
COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency.
复制标题
DOI：
10.1016/j.jaip.2020.11.042
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Valle SOR
中科院分区：
文献类型：
--
作者：
Grumach AS;Goudouris E;Dortas Junior S;Marcelino FC;Alonso MLO;Martins RO;Arpon MA;Valle SOR
对患有严重急性呼吸综合征冠状病毒2型感染的C1抑制剂缺乏或正常的遗传性血管性水肿患者进行临床表征，并评估2019年冠状病毒病对遗传性血管性水肿症状的影响。尽管C1抑制剂参与控制多个系统，但患者并未出现严重的2019冠状病毒病。在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行开始时，年龄超过60岁，高血压和糖尿病已被确定为2019冠状病毒病（COVID-19）严重病例的主要危险因素。关于COVID-19免疫发病机制的知识正在迅速增加。COVID-19的致病性并不局限于呼吸系统，相关炎症反应导致全身受累与疾病的严重程度相关。此外，血栓栓塞现象在临床和实验室检查中得到证实。1
Patients with hereditary angioedema with deficiency or normal C1 inhibitor who presented severe acute respiratory syndrome coronavirus 2 infection were clinically characterized and the impact of coronavirus disease 2019 on hereditary angioedema symptoms was evaluated. Despite C1 inhibitor involvement in controlling several systems, the patients did not present severe coronavirus disease 2019.At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, age more than 60 years, hypertension, and diabetes mellitus have been identified as the major risk factors for severe cases of coronavirus disease 2019 (COVID-19). The knowledge about COVID-19’s immunopathogenesis has been increasing rapidly. The pathogenicity of COVID-19 is not restricted to the respiratory system, and a relevant inflammatory response producing systemic involvement was associated with the severity of the disease. Also, thromboembolic phenomena were evidenced clinically and through laboratory tests. 1
DOI：
10.1016/j.ajem.2020.09.065
发表时间：
2021-01
期刊：
The American journal of emergency medicine
影响因子：
--
作者：
Avila J;Long B;Holladay D;Gottlieb M
通讯作者：
Gottlieb M
影响因子：
14.2
作者：
Cugno, Massimo;Meroni, Pier Luigi;Peyvandi, Flora
通讯作者：
Peyvandi, Flora
DOI：
10.1093/infdis/jiaa646
发表时间：
2021-02-03
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
de Nooijer AH;Grondman I;Janssen NAF;Netea MG;Willems L;van de Veerdonk FL;Giamarellos-Bourboulis EJ;Toonen EJM;Joosten LAB;RCI-COVID-19 study group
通讯作者：
RCI-COVID-19 study group